adeno-associated virus

Contents

adeno-associated virus

Introduction

Adeno-associated virus is a small, non-enveloped single-stranded DNA virus historically studied in the contexts of Jan Svoboda, Harold Varmus, Max Delbrück, Salvador Luria, and early molecular virology laboratories at institutions such as Cold Spring Harbor Laboratory, Rockefeller University, Massachusetts Institute of Technology, and University of Cambridge. First noted as a contaminant in studies involving Adenovirus preparations at research centers including Harvard University and Stanford University, it later became central to gene therapy development at organizations like Genzyme, Spark Therapeutics, uniQure, and academic groups at University of Pennsylvania and Stanford University School of Medicine. Its discovery and characterization intersected with events such as work by Wendell Stanley and techniques refined at The Pasteur Institute and National Institutes of Health. Regulatory and translational pathways for vectors derived from it engaged agencies like the Food and Drug Administration and milestones such as approvals involving Luxturna and clinical programs at Hospital for Sick Children and Great Ormond Street Hospital.

The virus belongs to the family Parvoviridae and the genus Dependoparvovirus, sharing structural features described in cryo-electron microscopy studies from teams at European Molecular Biology Laboratory and Max Planck Institute. Its ~4.7 kb single-stranded DNA genome encodes rep and cap open reading frames characterized by researchers at University of California, Berkeley, University College London, and Johns Hopkins University. The icosahedral capsid, ~25 nm in diameter, is built from VP1, VP2, and VP3 proteins studied in structural biology work at Scripps Research Institute and Cold Spring Harbor Laboratory, with antigenic serotypes defined by groups at Institut Pasteur, Weizmann Institute of Science, and Karolinska Institute. Serotypes such as those identified by investigators at Université Paris-Sud and University of Tokyo have been mapped for tissue specificity by consortia including researchers from California Institute of Technology and Yale University.

Replication requires helper virus functions provided by agents such as Adenovirus or Herpes simplex virus, an interaction described in reviews from National Institutes of Health laboratories and historical reports from Pasteur Institute collaborators. Entry pathways were elucidated by teams at Harvard Medical School and University of Oxford, implicating cellular receptors characterized in studies at University of California, San Francisco and University of Pennsylvania. Intracellular trafficking and uncoating were mapped in cell biology labs at MIT and Duke University, while second-strand synthesis and genome persistence in non-dividing cells were investigated by researchers at University of Washington and Vanderbilt University. Tropism differences among serotypes were leveraged by groups at University of Florida and McGill University to target tissues including liver, retina, muscle, and central nervous system regions examined at Mount Sinai Hospital and Mayo Clinic.

Vectors derived from this virus underpin approved gene therapies such as Luxturna and clinical programs pursued by companies including Spark Therapeutics, uniQure, Novartis, and Pfizer. Academic clinical trials at University of Pennsylvania, University College London, and Great Ormond Street Hospital explored uses in hemophilia, spinal muscular atrophy, and inherited retinal dystrophies, with translational contributions from Children's Hospital of Philadelphia and Nationwide Children's Hospital. Manufacturing scale-up and regulatory approvals involved collaborations with European Medicines Agency and Food and Drug Administration, while ethical and policy debates spanned forums at World Health Organization, National Academy of Medicine, and Royal Society. Outcomes and adverse-event monitoring have been reported by consortia including International Rare Diseases Research Consortium and national registries coordinated by National Health Service entities.

Pre-existing neutralizing antibodies and cell-mediated responses identified by immunology groups at Broad Institute, Rockefeller University, and La Jolla Institute for Immunology influence vector efficacy and were central to clinical exclusion criteria at centers like Mayo Clinic and Johns Hopkins Hospital. Innate sensing pathways involving pattern-recognition receptors were characterized by teams at Harvard T.H. Chan School of Public Health and Imperial College London. Safety signals, including hepatotoxicity and insertional concerns, were monitored in post-approval surveillance coordinated by Food and Drug Administration and European Medicines Agency, with long-term follow-up protocols influenced by guidelines from World Health Organization and advisory panels convened at National Institutes of Health.

Manufacturing platforms developed by industrial groups at Genzyme, Lonza, and Merck alongside academic process teams at UC Berkeley and Massachusetts General Hospital include transient transfection of HEK293 cells and baculovirus systems adapted by researchers at INRAE and Institut Pasteur. Capsid engineering, directed evolution, and rational design efforts were led by labs at California Institute of Technology, Salk Institute, and ETH Zurich, producing novel serotypes and synthetic capsids evaluated in preclinical studies at Stanford University and University of Michigan. Quality control, assays, and standardization involve collaborations with American Society for Gene & Cell Therapy and regulatory science groups at European Directorate for the Quality of Medicines.